Patrick Yeramian's Insider Trades & SAST Disclosures
Patrick Yeramian's most recent trade in Amylyx Pharmaceuticals Inc was a trade of 2,812 Common Stock done at an average price of $16.3 . Disclosure was reported to the exchange on Jan. 9, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Patrick Yeramian.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 09 Jan 2024 | 2,812 | 205,605 | - | 16.3 | 45,915 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.03 per share. | 15 May 2023 | 11,965 | 208,417 | - | 29.0 | 347,358 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 9,764 | 33,770 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 15 May 2023 | 9,764 | 220,382 | - | 6.9 | 67,176 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 2,201 | 15,404 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 15 May 2023 | 2,201 | 210,618 | - | 0.4 | 814 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.53 per share. | 17 Apr 2023 | 49,279 | 208,717 | - | 30.5 | 1,504,660 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2023 | 44,861 | 17,605 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 17 Apr 2023 | 44,861 | 253,278 | - | 0.4 | 16,599 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2023 | 4,718 | 43,534 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 17 Apr 2023 | 4,718 | 257,996 | - | 6.9 | 32,460 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.94 per share. | 17 Apr 2023 | 300 | 208,417 | - | 30.9 | 9,282 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.85 per share. | 16 Mar 2023 | 52,211 | 201,666 | - | 31.8 | 1,662,842 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 41,250 | 41,250 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 30,041 | 62,466 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 16 Mar 2023 | 30,041 | 237,129 | - | 0.4 | 11,115 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 16 Mar 2023 | 16,748 | 253,877 | - | 6.9 | 115,226 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 16,748 | 48,252 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 9,167 | 208,417 | - | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.33 per share. | 16 Mar 2023 | 2,789 | 207,088 | - | 0.3 | 920 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 2,789 | 0 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.43 per share. | 16 Mar 2023 | 2,416 | 199,250 | - | 32.4 | 78,358 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.08 per share. | 06 Jan 2023 | 1,405 | 204,928 | - | 36.1 | 50,691 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 06 Jan 2023 | 629 | 204,299 | - | 36.8 | 23,140 | Common Stock |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 127,500 | 127,500 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Patrick Yeramian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 28,333 | 206,333 | - | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges